Hemostemix Inc.
HEM
Rankning i aktier
#32549
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Aktiekurs
$0.04268108
Senast synkroniserad: 2026-10-21
Marknadsvärde
$9.02M
Förändring (1 dag)
5.73%
Förändring (1 år)
-42.09%
Land
CA
Handel Hemostemix Inc. (HEM)
Kategori
Healthcare
Aktiekurshistorik för Hemostemix Inc. (HEM)
Högsta slutkurs: $0.04 den 2026-10-01
Lägsta slutkurs: $0.00 den 2005-11-01
Lägsta slutkurs: $0.00 den 2005-11-01
Aktiekurshistorik för Hemostemix Inc. från 2005 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | -11.95% |
| 2025 | 20.30% |
| 2024 | -2.01% |
| 2023 | -53.19% |
| 2022 | -8.06% |
| 2021 | 925.13% |
| 2020 | 7.84% |
| 2019 | -99.16% |
| 2018 | 984,477.83% |
| 2017 | 242.51% |
| 2016 | -91.14% |
| 2015 | 0.00% |
| 2014 | 0.00% |
| 2013 | 0.00% |
| 2012 | 0.00% |
| 2011 | 0.00% |
| 2010 | -1.41% |
| 2009 | -34.26% |
| 2008 | -72.09% |
| 2007 | 17.99% |
| 2006 | 72.63% |
| 2005 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $536.71 | 25.86% |
US
|
|
| $192.49 | 616.91% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $883.40 | 8.50% |
NL
|
